Advertisement

Erratum

    Published:February 01, 2021DOI:https://doi.org/10.1016/j.jtho.2020.10.003
        In the article titled “BRAF-Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience” (J Thorac Oncol. 2019;14[3]:e57–e59), one of the coauthors, Dr. Angelo Delmonte, was listed with an incomplete affiliation. It should be Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy.

        Linked Article

        • BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience
          Journal of Thoracic OncologyVol. 14Issue 3
          • Preview
            Dudnik et al.1 described in this Journal their multi-institutional retrospective analysis assessing the prevalence of programmed death ligand 1 (PD-L1) expression, as well as total mutation burden (TMB) and microsatellite instability, in a cohort of 39 BRAF-mutant advanced NSCLC patients, of which 22 were treated with immune checkpoint inhibitors (ICPis). The results of this study show that BRAF-mutant NSCLC is associated with a high level of PD-L1 expression and low/intermediate TMB and microsatellite-stable status.
          • Full-Text
          • PDF
          Open Archive